Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

181.21 -1.73 (-0.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
Where Axsome Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required ↗
The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028. 
Via Benzinga
News headline image
Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews ↗
 
Via Benzinga
News headline image
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability ↗
The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review. 
Via Stocktwits
Topics Stocks
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗
 
Via Benzinga
News headline image
2 Soaring Stocks Wth More Upside Potential ↗
Via The Motley Fool
News headline image
Why Is Teva Stock Trading Higher On Tuesday? ↗
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
News headline image
3 High-Flying Stocks That Could Soar Even More ↗
Via The Motley Fool
News headline image
Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts ↗
 
Via Benzinga
News headline image
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis ↗
Via The Motley Fool
News headline image
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years ↗
Via The Motley Fool
News headline image
3 Monster Stocks in the Making ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1 ↗
Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs. 
Via Benzinga
News headline image
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings) ↗
 
Via Benzinga
News headline image
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Stocks Edge Higher Despite Trade, Economic Jitters ↗
Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Why Shares of Axsome Therapeutics Slumped Today ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week ↗
The company posted mixed results for its depression treatment, noting it appears to work in a smaller patient group. 
Via Investor's Business Daily
News headline image
Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder ↗
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025. 
Via Benzinga
News headline image
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗
Via The Motley Fool
News headline image
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. ↗
The company is working on a non-stimulant approach to treating ADHD. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal ↗
Axsome's solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile. 
Via Benzinga
News headline image
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs ↗
Axsome's Symbravo outperformed oral CGRP inhibitors in a Phase 3 trial, improving migraine pain relief, symptom control, and return to daily activities. 
Via Benzinga
News headline image
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride ↗
CEO Herriot Tabuteau struck an optimistic tone, citing strong commercial growth, a rapidly advancing pipeline, and the recent U.S. approval of Symbravo for migraine treatment. 
Via Stocktwits
News headline image
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday? ↗
Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday. 
Via Benzinga
News headline image
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.